Evidence boundary: This article reviews published, registered, patent, and regulatory research involving the specific ipamorelin substances, formulations, populations, and study conditions identified in the cited sources. Findings involving ghrelin, other growth-hormone secretagogues, GHRH analogues, combination protocols, or separately manufactured materials cannot be transferred automatically to ipamorelin. Nothing here is a claim about an FDB research product, a recommendation for human use, or medical advice. First Due Biotech products are offered strictly for laboratory research use only and are not for human consumption.
What is ipamorelin?
Ipamorelin, development code NNC 26-0161, is a synthetic amidated pentapeptide developed within Novo Nordisk’s growth-hormone-secretagogue research program. Its sequence is Aib–His–D-2-Nal–D-Phe–Lys–NH₂, where Aib and D-2-Nal are non-proteinogenic amino-acid residues.
Unlike GHRH analogues such as tesamorelin or Modified GRF (1-29), ipamorelin acts through the ghrelin/growth-hormone-secretagogue receptor, GHS-R1a. Activation of this receptor can stimulate a transient release of endogenous growth hormone through hypothalamic and pituitary pathways.
Ipamorelin attracted scientific interest because early animal experiments suggested a more focused endocrine response than older secretagogues such as GHRP-2 and GHRP-6. It later progressed into human pharmacokinetic research and a clinical development program examining postoperative gastrointestinal recovery.
The resulting evidence base is compact but informative: acute human growth-hormone target engagement was demonstrated, several animal models produced functional findings, and a clinical hypothesis was tested in randomized trials. The principal published patient trial, however, did not meet its primary endpoint, and the largest completed trial remains unpublished.
Why researchers studied it
Earlier growth-hormone-releasing peptides could stimulate growth hormone while also changing other pituitary-adrenal markers in some experimental systems. Researchers sought shorter molecules that retained growth-hormone release while reducing those broader endocrine responses.
In the foundational 1998 study, ipamorelin stimulated growth-hormone release in rat pituitary cells, rats, and conscious swine. In the conscious-swine comparison, investigators did not observe significant changes in ACTH or cortisol after ipamorelin, while comparator secretagogues affected those markers. FSH, LH, prolactin, and TSH also did not change significantly in that experiment.
This was a meaningful early pharmacodynamic result and explains why the paper described ipamorelin as a selective growth-hormone secretagogue. The word “selective” needs a precise boundary, though. The experiment demonstrated a comparatively focused hormone pattern in swine; it did not establish exclusive binding to GHS-R1a, broad molecular selectivity, or cortisol and prolactin neutrality in humans.
Research at a glance
| Research area | What the identified evidence reported | Evidence assessment |
|---|---|---|
| Molecular identity | A defined amidated pentapeptide; free-base and acetate terminology is inconsistently applied across sources | Strong for the core sequence; material form still requires verification |
| Receptor pathway | Functional research supports ghrelin/GHS-R1a agonism and growth-hormone release | Established proximal pharmacology |
| Acute human GH response | A controlled healthy-volunteer study reported systemic exposure and a short-lived GH episode | Direct human target engagement |
| Human PK | The same acute study reported approximately linear disposition and a terminal half-life near two hours under its conditions | Limited, single-study evidence |
| Human endocrine selectivity | Cortisol, ACTH, prolactin, and other selectivity markers were not established in the identified human studies | Unproven in humans |
| Postoperative gastrointestinal recovery | One randomized Phase 2 trial reported a numerical difference but missed its primary endpoint and found no significant secondary efficacy differences | Clinical benefit not demonstrated |
| Larger Phase 2 program | A completed 320-participant trial is registered without posted results or an identified publication | Outcome unknown |
| Growth, bone, feeding, GI transit, catabolic, and pain models | Multiple animal studies reported functional or surrogate signals, with important null and adverse-direction findings | Broad but model-specific preclinical evidence |
| Human body composition, sleep, healing, cognition, or performance | No direct ipamorelin-only outcome study was identified | Not established |
| Human safety | One short surgical trial supplies a limited safety dataset; long-term characterization is absent | Inadequate for broad conclusions |
How ipamorelin engages the GH axis
GHS-R1a is the receptor most closely associated with ghrelin and synthetic growth-hormone secretagogues. In pituitary and hypothalamic systems, its activation can promote growth-hormone release when functional pituitary capacity remains.
The strongest ipamorelin-specific evidence concerns this proximal step. Rat pituitary-cell experiments demonstrated functional secretion, animal studies repeatedly reported growth-hormone responses, and the healthy-volunteer study showed an acute human growth-hormone pulse.
That is a real pharmacodynamic finding, but it should not be expanded into an outcome claim. A transient hormone response is not direct evidence of changes in body composition, tissue repair, sleep, cognition, strength, longevity, or clinical recovery. Those questions require studies that measure those endpoints.
Modern GHS-R1a research also discusses Gq/11 signaling, calcium mobilization, β-arrestin recruitment, receptor trafficking, and ligand-biased signaling. These mechanisms are relevant background for the receptor class. The identified literature did not include an ipamorelin-specific modern binding panel, broad off-target screen, β-arrestin comparison, or receptor-structure study, so those details should not be presented as verified features of ipamorelin itself.
The acute human pharmacology study
Gobburu and colleagues published the principal human pharmacokinetic and pharmacodynamic study in 1999. Healthy male volunteers received a single systemic exposure under controlled research conditions.
Investigators reported approximately linear pharmacokinetics described by a two-compartment model. The reported terminal half-life was about two hours, and growth hormone peaked within the first hour before declining toward negligible concentrations over the following hours. Pharmacodynamic variability between participants was greater than pharmacokinetic variability.
This study established two useful points:
- Ipamorelin reached systemic circulation with measurable disposition under the investigated conditions.
- It produced a brief, measurable human growth-hormone response.
The study was small and designed for acute PK/PD characterization, not therapeutic outcomes. It did not establish sustained IGF-1 change, repeat-exposure behavior, body-composition effects, long-term endocrine adaptation, or clinical benefit. Public sources also do not provide a complete adverse-event account.
The approximately two-hour value belongs to that particular systemic study. It should not be converted automatically into pharmacokinetics for another route, formulation, salt form, or separately manufactured material.
The postoperative-ileus research program
Ipamorelin’s main clinical-development program examined postoperative ileus—delayed gastrointestinal recovery after bowel surgery. The rationale arose from animal studies in which investigators reported improvements in gastric emptying, intestinal transit, fecal output, feeding, or contractile responses following surgical manipulation.
Those preclinical findings were sufficiently encouraging to support randomized human testing.
In the published Phase 2 proof-of-concept trial, 117 bowel-resection patients were enrolled and 114 received study treatment. Participants were randomly assigned to ipamorelin or placebo. The primary endpoint measured the time until a standardized solid meal could be tolerated without nausea or vomiting.
Median time was numerically shorter in the ipamorelin group—25.3 hours versus 32.6 hours—but the difference was not statistically significant at p=0.15. Key and secondary efficacy analyses also did not show significant differences. An exploratory subgroup signal in participants undergoing open laparotomy could not overturn the negative primary result.
This trial is scientifically useful even though it was not positive. It tested a plausible animal-derived hypothesis in a controlled clinical setting and demonstrated that model-specific prokinetic activity did not translate into established clinical efficacy under the trial conditions.
A separate, larger Phase 2 study, NCT01280344, enrolled 320 participants and is recorded as completed. It compared multiple ipamorelin regimens with placebo after open bowel resection. No results were posted and no peer-reviewed results publication was identified through the evidence cutoff. Its primary outcome and adverse-event results must therefore be described as unknown—not positive and not negative.
What the animal evidence adds
Ipamorelin has been studied across a wider range of animal questions than the human literature alone would suggest. Reported areas include:
- Longitudinal growth and bone-related measurements in rats
- Feeding, body weight, adiposity, and leptin in mice
- Nitrogen balance and muscle-force measures during glucocorticoid-associated catabolism
- Gastrointestinal recovery after surgical manipulation
- Weight change during cisplatin challenge in ferrets
- Visceral and somatic pain-behavior models in rats
- Growth-hormone and IGF-1 signaling in diabetic mice
Several findings were functionally interesting. Rat studies reported longitudinal growth and size-related bone-mineral changes. Catabolic models reported nitrogen-balance or force-related signals. Postoperative models reported gastrointestinal transit improvements. A receptor-antagonist experiment supported GHS-R involvement in rat pain-behavior effects.
The same literature also prevents a one-directional interpretation. Some models reported increased food intake, body weight, or relative adiposity rather than fat loss. Bone size or mineral content changed without improved volumetric density. A strong growth-hormone pulse failed to restore IGF-1 in diabetic mice. Gastrointestinal results varied across models, and the later clinical trial was negative. A ferret study reported less delayed weight loss during cisplatin challenge but no antiemetic effect and an ex-vivo inhibitory effect on ileal contractions.
These studies demonstrate biological breadth, not a catalog of human benefits. Species, disease model, challenge condition, endpoint, and combination exposure remain part of every result.
Body composition, appetite, and metabolic claims
No ipamorelin-only human study establishing fat loss, lean-mass gain, appetite neutrality, glucose improvement, or insulin-sensitivity improvement was identified.
The animal literature is especially important here because its direction does not consistently match popular summaries. In GH-deficient and GH-intact mice, investigators reported increased food intake and relative adiposity, suggesting that some effects may occur independently of growth-hormone secretion. This does not establish the same response in humans, but it directly argues against presenting fat loss or lack of appetite effect as settled properties.
Sustained human IGF-1 elevation was also not established in the identified ipamorelin-only studies. The acute GH response should not be treated as proof that every downstream marker or body-composition endpoint will change.
Combination claims and evidence transfer
Ipamorelin is frequently discussed alongside CJC-1295 without DAC, CJC-1295 with DAC, sermorelin, or tesamorelin. These pairings do not create a shared evidence base.
GHRH analogues and GHS-R1a agonists act through different upstream receptors, which provides a mechanistic reason researchers might study combined signaling. No identified controlled human study established the safety, endocrine response, pharmacokinetics, body-composition effects, or clinical benefit of an ipamorelin/CJC combination.
Likewise, human findings involving other ghrelin-receptor agonists or growth-hormone secretagogues cannot be assigned to ipamorelin without a validated bridge. Structural relatives can inform research hypotheses; they cannot supply molecule-specific effect sizes.
Safety and material-quality questions
Public human safety information is limited primarily to the short postoperative trial. Treatment-emergent events were common in both study groups within a high-risk surgical setting. FDA’s reconstruction found broadly similar serious-event proportions, although numerical imbalances appeared in selected measures. Two deaths occurred in the ipamorelin arm following severe postoperative complications; the available record did not establish causality.
That dataset is too small, short, and clinically confounded to characterize long-term safety. No complete public package was identified for chronic toxicology, genotoxicity, reproductive or developmental toxicity, carcinogenicity, dedicated safety pharmacology, or validated clinical immunogenicity.
The chemistry question is also material. FDA separately evaluated ipamorelin free base and ipamorelin acetate and documented inconsistent naming and certificate information. Public sources also describe a specific diacetate formulation and report trifluoroacetate material in early research. These labels should not be treated as interchangeable without analytical confirmation.
For peptide research, sequence identity alone does not resolve purity, counterion, related-sequence impurities, aggregation, residual synthesis materials, endotoxin, bioburden, sterility, or particulates. Findings for a defined clinical formulation cannot establish the characteristics of a separately produced material bearing the same compound name.
Regulatory and anti-doping context
No FDA-approved drug containing ipamorelin was identified. FDA’s 2024 Pharmacy Compounding Advisory Committee review evaluated the free base and acetate for growth-hormone deficiency and postoperative ileus and recommended against adding either substance to the Section 503A Bulks List. The advisory committee voted 0 in favor and 12 against inclusion.
That proceeding was a compounding evaluation, not a drug-approval trial, and an advisory vote should not be described as final rulemaking by itself. Its scientific review remains important because it examined identity, characterization, effectiveness, and safety separately.
The World Anti-Doping Agency’s 2026 Prohibited List explicitly names ipamorelin among growth-hormone-releasing factors prohibited at all times. Sports-governing rules and regulatory status should be rechecked before publication because both can change.
Why the evidence remains scientifically important
Ipamorelin offers a useful translational research story. A short synthetic peptide demonstrated functional GHS-R-pathway activity, produced a measurable acute growth-hormone response in humans, and generated enough gastrointestinal evidence in animals to justify controlled clinical trials.
The program also shows why advancing through research stages matters. Proximal target engagement was real; the proposed patient benefit was not confirmed in the published trial. That distinction does not diminish the pharmacology. It defines what the compound has demonstrated and identifies the next unanswered questions.
A stronger future program would require clearly characterized material, modern receptor profiling, repeat-exposure human PK/PD where legally and ethically authorized, complete endocrine-marker assessment, transparent publication of the larger Phase 2 dataset, and endpoint-specific studies rather than inference from a growth-hormone pulse.
The most evidence-aligned conclusion is specific and constructive: ipamorelin is a biologically active GHS-R1a research compound with demonstrated acute human GH target engagement and varied preclinical findings, while broad clinical benefits and long-term safety remain unestablished.
Key takeaways
- Ipamorelin is an amidated pentapeptide and ghrelin/GHS-R1a agonist candidate developed as a growth-hormone secretagogue.
- Early swine research reported a more focused endocrine pattern than selected older secretagogues, but human cortisol, ACTH, and prolactin neutrality has not been established.
- A controlled healthy-volunteer study demonstrated systemic exposure and a brief human growth-hormone response.
- The published postoperative-ileus trial reported a numerical difference but missed its primary endpoint and did not establish clinical efficacy.
- A larger completed Phase 2 trial enrolled 320 participants, but its results were not publicly available through the evidence cutoff.
- Animal studies reported functional findings across growth, catabolic, gastrointestinal, feeding, weight, and pain models, with important null and adverse-direction results.
- No direct human evidence was identified for body composition, sleep, healing, cognition, physical performance, or longevity.
- Combination claims involving CJC-1295 or other secretagogues remain unestablished in controlled human research.
- Free-base, acetate, diacetate, and other material descriptions require careful identity and formulation control.